Therapeutic Mitochondria Transfer for Anti

Cellvie is at the forefront of developing Therapeutic Mitochondria Transplantation, a groundbreaking approach aimed at enhancing cellular energy metabolism by addressing mitochondrial dysfunction. Mitochondria, known as the powerhouses of the cell, are crucial for generating ATP, the energy currency necessary for various cellular functions. Cellvie's innovative technique involves the augmentation and replacement of damaged mitochondria, which can significantly improve energy production and overall cell function. The company is initially focusing on ischemia-reperfusion injury, a critical medical condition that arises when blood flow is interrupted and then restored, leading to significant cellular damage. This condition is particularly relevant in scenarios such as heart attacks, strokes, and organ transplantation, with the first application targeting kidney transplantation to reduce the incidence of delayed graft function.

The technology employed by Cellvie not only aims to restore energy production but also addresses other vital mitochondrial roles, including calcium homeostasis, programmed cell death, and metabolite production. By utilizing proprietary preparation and delivery methods, Cellvie's approach allows for the direct transplantation of mitochondria into compromised cells, enhancing their energy metabolism and potentially reversing degenerative processes associated with aging and various diseases. This novel treatment modality holds promise for a wide range of applications beyond ischemia-reperfusion injury, as the company seeks to explore its potential in treating conditions linked to mitochondrial dysfunction, thereby paving the way for new therapeutic avenues in regenerative medicine.

Switzerland

cellvie is the leader in Therapeutic Mitochondria Transplantation (TMT).

The team is seeking to bring about a novel treatment modality, leveraging the therapeutic potential of mitochondria, the powerhouses of the cell.

Therapeutic Mitochondria Transplantation, an approach for mitochondria augmentation and replacement, was developed by Dr. James McCully at Harvard Medical School. cellvie was founded to take this technology from bench to bed, starting in heart attacks and solid organ transplantation.

Cellvie

Company Details